Overview
Hitachi High-Tech Corporation (Hitachi High-Tech) announced that Roche and Hitachi High-Tech have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies’ expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the two companies’ long-standing partnership.
Collaboration for Innovation
- Roche and Hitachi High-Tech have been collaborating to bring innovative new diagnostics to those that need them most since 1978.
- Today the collaboration has resulted in an unrivalled global reach of over 84,000 installed diagnostic units worldwide.
- Together Roche and Hitachi High-Tech have brought numerous innovations to the field of in-vitro diagnostics including the pioneering ‘serum work area’ concept that integrates clinical chemistry and immunochemistry into one system.
Both Roche and Hitachi High-Tech share the vision to drive innovation in in-vitro diagnostics to solve healthcare challenges of today and in the future.
Hitachi High-Tech will continue to contribute to improving people’s QoL (Quality of Life) around the world and create “a society without fear of cancer”.
Roche
- Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.
- The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.
Hitachi High-Tech
Hitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment.
